Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN

User menu

  • Subscribe
  • My alerts
  • My Cart
  • Log in

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN
  • Subscribe
  • My alerts
  • My Cart
  • Log in
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Review

Adverse events associated with immune checkpoint inhibitor treatment for cancer

Khashayar Esfahani, Nicholas Meti, Wilson H. Miller and Marie Hudson
CMAJ January 14, 2019 191 (2) E40-E46; DOI: https://doi.org/10.1503/cmaj.180870
Khashayar Esfahani
Department of Medicine (Esfahani, Meti, Miller, Hudson), McGill University; Departments of Medicine and Oncology (Esfahani, Miller), McGill University and Jewish General Hospital, Rossy Cancer Network; Division of Rheumatology and Lady Davis Institute (Hudson), Jewish General Hospital, Montreal, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Meti
Department of Medicine (Esfahani, Meti, Miller, Hudson), McGill University; Departments of Medicine and Oncology (Esfahani, Miller), McGill University and Jewish General Hospital, Rossy Cancer Network; Division of Rheumatology and Lady Davis Institute (Hudson), Jewish General Hospital, Montreal, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wilson H. Miller
Department of Medicine (Esfahani, Meti, Miller, Hudson), McGill University; Departments of Medicine and Oncology (Esfahani, Miller), McGill University and Jewish General Hospital, Rossy Cancer Network; Division of Rheumatology and Lady Davis Institute (Hudson), Jewish General Hospital, Montreal, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie Hudson
Department of Medicine (Esfahani, Meti, Miller, Hudson), McGill University; Departments of Medicine and Oncology (Esfahani, Miller), McGill University and Jewish General Hospital, Rossy Cancer Network; Division of Rheumatology and Lady Davis Institute (Hudson), Jewish General Hospital, Montreal, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

CMA Member Access

CMA Members please log in below using your CMAJ account.

If you don't remember your CMAJ login, click here to reset it.

If you don't have a CMAJ account and know your CMA membership number, click here to create an account. If you don't know your CMA membership number, contact the Member Service Centre via telephone at 888-855-2555 ext. 8004 (Canada & Continental US only); 613-731-8610 ext. 8004 or via email at [email protected].

Log in using your username and password

Forgot your user name or password?

Log in through your institution

You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 191 (2)
CMAJ
Vol. 191, Issue 2
14 Jan 2019
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Adverse events associated with immune checkpoint inhibitor treatment for cancer
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
Citation Tools
Adverse events associated with immune checkpoint inhibitor treatment for cancer
Khashayar Esfahani, Nicholas Meti, Wilson H. Miller, Marie Hudson
CMAJ Jan 2019, 191 (2) E40-E46; DOI: 10.1503/cmaj.180870

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Adverse events associated with immune checkpoint inhibitor treatment for cancer
Khashayar Esfahani, Nicholas Meti, Wilson H. Miller, Marie Hudson
CMAJ Jan 2019, 191 (2) E40-E46; DOI: 10.1503/cmaj.180870
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • What are immune checkpoint inhibitors and how do they work?
    • Why do immune-related adverse events occur?
    • How are immune-related adverse events diagnosed and managed?
    • What is the impact of immune-related adverse events on cancer outcomes?
    • Are immune checkpoint inhibitors suitable for patients with pre-existing autoimmune diseases?
    • Can we predict which patients will develop immune-related adverse events?
    • Conclusion
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • Scopus
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Identifying and managing younger women at high risk of cardiovascular disease
  • Management of gender dysphoria in adolescents in primary care
Show more Review

Similar Articles

Collections

  • Topics
    • Drugs: immunologic
    • Immunology
    • Drugs: adverse reactions
    • Cancer & oncology
    • Autoimmune disease

Content

  • Current issue
  • Past issues
  • Early releases
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Videos
  • Alerts
  • RSS

Information for

  • Advertisers
  • Authors
  • CMA Members
  • Media
  • Permission requests
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact

Copyright 2018, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire